Crossmark

Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors

Crossref DOI link: https://doi.org/10.1038/s41388-019-0965-5

Published Online: 2019-08-23

Published Print: 2019-09-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ki, Dong Hyuk http://orcid.org/0000-0002-1571-7077
Oppel, Felix http://orcid.org/0000-0003-1011-1954
Durbin, Adam D. http://orcid.org/0000-0002-5472-9847
Look, A. Thomas http://orcid.org/0000-0001-7851-8617
Funding

Funding for this research was provided by:

1. Mildred-Scheel-Postdoctoral program of the Mildred Scheel Foundation

Damon Runyon Cancer Research Foundation (DRSG-24-18)

Alex's Lemonade Stand Foundation for Childhood Cancer (Young Investigator Award)

American Society of Clinical Oncology (Young Investigator Award)

Rally Foundation (Young Investigator Award)
License Information

Text and Data Mining valid from 2019-08-23

Version of Record valid from 2019-08-23
More Information

Article History

Received: 14 November 2018

Revised: 8 May 2019

Accepted: 27 May 2019

First Online: 23 August 2019

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below